Form 4: iBio Director Granted 13,500 Stock Options

iBio, Inc. Director William D. Clark received a grant of 13,500 stock options with an exercise price of $1, vesting monthly over twelve months.

Summary

• William D. Clark, a Director of iBio, Inc. (IBIO), was granted 13,500 stock options.
• The transaction date for this grant was November 20, 2025.
• Each option has an exercise price of $1.
• The options vest pro rata on a monthly basis over twelve months, commencing from the grant date.
• The options have an expiration date of November 19, 2035.
• Following this transaction, William D. Clark beneficially owns 13,500 derivative securities directly.

Sentiment

Score: 6

Explanation: Slightly positive, as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. No negative financial or operational news is present.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration date, providing a long-term incentive horizon.

Negatives

• No specific negative information is disclosed in this Form 4 filing.

Risks

• The value of the stock options is dependent on the future performance of iBio, Inc.'s stock price. If the stock price does not exceed the exercise price of $1, the options may expire worthless.

Future Outlook

The stock options are designed to vest over a twelve-month period, indicating a future incentive structure for the director. The long expiration date suggests a long-term view on the company's potential.

Industry Context

Insider transactions, such as stock option grants, are a common form of executive and director compensation in publicly traded companies, particularly in the biotechnology sector where long-term development cycles are prevalent. These grants aim to align the interests of key personnel with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a standard practice across various industries, including biotechnology, to incentivize performance and retention.
• An exercise price of $1, while specific to this grant, is common for options granted at or near the market price at the time of grant, or as a nominal value for certain types of grants.
• A 10-year expiration period for stock options is typical for long-term incentive plans in many U.S. public companies.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholders, potentially leading to decisions that enhance long-term shareholder value.

Next Steps

• The stock options will vest pro rata on a monthly basis over the next twelve months, starting from November 20, 2025.

Key Dates

Keywords

iBio, IBIO, stock options, director, insider transaction, Form 4, equity compensation, corporate governance